Quantitative Modeling of the High-Throughput Production and In Vivo Kinetics of (Drug-Encapsulating) Liposomes

Albert Wong*

Program in Biological and Biomedical Sciences, Yale University, New Haven, Connecticut, United States of America

Abstract

In developing liposomes for in vivo use, it is important to design the liposomes to have optimal in vivo kinetics, and it is also necessary to identify optimal high-throughput production conditions for these liposomes. Previous work has not definitively established the general relationship between liposomes’ configuration and composition, and their in vivo kinetics. Also, no straightforward method exists to calculate optimal liposome high-throughput production conditions for specific lipidosome compositions. This work presents first-principles quantitative correlations describing liposomes’ in vivo drug leakage and vascular mass transfer kinetics. This work further presents a simple quantitative model relating specific liposome compositions to ideal high-throughput production parameters. The results have implications for the identification of promising lipidosome compositions via high-throughput screening methodologies, as well as the design and optimization of high-throughput reactors for liposome production.

Citation: Wong A (2010) Quantitative Modeling of the High-Throughput Production and In Vivo Kinetics of (Drug-Encapsulating) Liposomes. PLoS ONE 5(4): e10280. doi:10.1371/journal.pone.0010280

Editor: Christophe Eghes, Tufts University, United States of America

Received December 8, 2009; Accepted March 29, 2010; Published April 23, 2010

Copyright: © 2010 Albert Wong. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by funding from the MIT Office of the Provost and the MIT Portugal Program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The author has declared that no competing interests exist.

* E-mail: albert.wong@yale.edu

Introduction

Many drugs are attendant with significant systemic risks and side effects. To allow these drugs to achieve the treatment ideality of maximal efficacy and maximal specificity, it is necessary to use a targeted drug carrier to deliver and release the drugs specifically at the right time and at the right location [1].

Closed phospholipid vesicles (i.e., liposomes) are widely used as targeted drug carriers to deliver and release drugs in appropriate amounts at specific times and specific locations in the body. Existing liposomes exhibit undesirable in vivo characteristics including intrinsic destabilization, drug leakage, immunogenicity, and short plasma half-life [2]. Hence, research toward developing better liposomes is of significant importance.

Liposomes with optimal in vivo characteristics can be developed with knowledge of potential liposome compositions’ in vivo kinetics. The in vivo kinetics of some liposome compositions have been characterized by experimental studies [3]. However, for rapid high-throughput screening of potential liposome compositions, it would be ideal to have broadly valid correlations allowing the prediction of liposomes’ in vivo kinetics for many different liposome compositions.

Also, it is important to identify optimal high-throughput industrial liposome production conditions for liposome compositions of interest. While efficient industrial production conditions have been experimentally identified (mostly through trial and error) for some liposome compositions [3], it would be ideal to have a broadly valid quantitative model allowing the prediction of optimal production conditions for many different liposome compositions.

This work presents generally valid quantitative models describing liposomes’ high-throughput production and predicting liposomes’ in vivo drug leakage and vascular mass transfer kinetics for many liposome compositions.

Results

Encapsulated drug leakage from multilamellar liposome vesicles (MLVs)

Drug leakage from a widely used type of liposome, multilamellar liposomes (MLVs), is inherently minimized relative to drug leakage from one-layer, or unilamellar, liposomes due to MLVs’ basic configuration (Figure 1 – artist’s rendition of a cross section of a spherically symmetric, homogeneous, drug-encapsulating MLV). Via the general species conservation equation [4], drug leakage over time from a spherically symmetric, homogenous, drug-encapsulating MLV can be described by the following series:

\[
\frac{C}{C_0} (\eta, \tau) = \sum_{n=1}^{\infty} 2 \frac{k_C R}{D} \left[ 1 - \frac{k_C R}{D} \right] \frac{\sin \lambda_n \sin \lambda_n \eta \exp \left[ -\lambda_n^2 \tau \right]}{\eta \lambda_n^2} \]

where:

\[
\lambda_n = \left( 1 - \frac{k_C R}{D} \right) \tan \lambda_n; \quad \eta = \frac{r}{R}; \quad \tau = \frac{D}{R^2} t
\]
C = concentration of a given drug in a MLV
C₀ = initial (immediate post-loading) concentration of the drug in the MLV
D = diffusivity of the drug in the MLV
kₐ = mass transfer coefficient of the drug
R = radius of the MLV

Here, the term “homogeneous” is used to refer to the drug particles being evenly mixed with the lipid molecules throughout the MLV.


dumping mass transfer

A critically important issue associated with using liposomes in biological systems is the question of how the liposomes migrate in the bloodstream (Figure 2). From the general linear momentum conservation equation [4]–[6], the mass transfer of liposomes (of any type) in a blood vessel as a function of axial position can be described as:

\[ \frac{d}{dz} \left( \frac{C_b}{C_o} \right) = \frac{2z}{RU} k_0 (k_m + k_t) + k_m k_t \]

where:

\[ U = \frac{R^2 d \mathcal{P}}{8 \mu dz} \]

Cₐ = bulk liposome concentration in a vessel
C₀ = initial (inlet) liposome concentration
kₐ = mass transfer coefficient of the liposomes in the bloodstream
k_m = mass transfer coefficient of the liposomes in the vessel wall
k_t = mass transfer coefficient of the liposomes in the tissue space
\( \mathcal{P} \) = dynamic pressure in the vessel
R = radius of the blood vessel

\[ \mu = \text{dynamic viscosity of the blood} \]
\[ U = \text{mean velocity of fluid flow in the vessel} \]

High-throughput continuous tubular reactor (CTR) production rate

A highly efficient method for producing large quantities of drug-encapsulating liposomes rapidly comprises using a continuous flow reactor that can be run indefinitely as long as adequate quantities of reagents are supplied [7]. For these CTRs, a mole balance equation [8] can be used to develop a set of differential equations governing the liposome synthesis reaction. For example, for drug-encapsulating liposomes with targeting moieties (e.g., liposome-surface receptors), the synthesis reaction can be represented as follows, based on experimental measurements [9]–[11] of typical numbers of targeting moieties/receptors, drug particles, and lipid molecules per liposome (Figure 3):

\[ 100 \text{ Targeting Receptors (TR) (l)} + 10000 \text{ Drug (DRG) (l)} + 80000 \text{ Lipid (LIP) (s)} \rightarrow \text{Liposome (DEL) (l)} \]

Assuming pseudo-second order kinetics with a large excess of lipid (LIP) [9]–[11], the governing differential equations are:

\[ \frac{d[TR]}{dL} = - \frac{1}{u} \left( \frac{400}{d} k \right) [TR][DRG] \]

\[ \frac{d[DRG]}{dL} = - \frac{1}{u} \left( \frac{40000}{d} k \right) [TR][DRG] \]

\[ \frac{d[DEL]}{dL} = \frac{4}{u} \left( \frac{4}{d} k \right) [TR][DRG] \]

where:

\[ d = \text{CTR diameter} \]
\[ k = \text{reaction rate coefficient} \]
\[ u = \text{feed flow rate in the CTR} \]

Discussion

This work presents first principles quantitative correlations characterizing the core rate processes associated with the high-throughput production and in vivo kinetics of (drug-encapsulating...
liposomes. Specifically, the models describe liposomes’ encapsulated drug leakage kinetics, vascular mass transfer kinetics and high-throughput production kinetics.

The models can be used to facilitate the high-throughput screening of drug-encapsulating liposome compositions, configurations, and/or synthesis methods, with modeling data output employed as a preliminary rapid and low-cost filter in evaluating many different drug-encapsulating liposome compositions, configurations, and synthesis procedures. For example, the models could be used to screen different drugs to see which drugs, based on known biophysical properties, could potentially be carried and delivered effectively by a MLV. Also, the models could be used to screen different lipid modifications to see what kinds of modifications (based on known biophysical properties) might minimize undesired leakage of a particular drug. Other applications are also possible.

Compositions, configurations, or synthesis methods deemed to be promising based on the modeling output could then be further tested and characterized experimentally. Such a screening methodology is particularly important because past efforts to identify effective novel compositions, configurations, or synthesis methods have been limited due to an almost exclusive reliance on direct experimental testing. High-throughput screening using these models hence provides a way to test many more compositions, configurations, and synthesis methods (and identify more promising candidates) than experimental testing alone.

Further work may be performed to test and adapt these models for specific experimental conditions in practice. Also, future studies could extend these models to cover additional classes of liposomes and to other biologically relevant micro- and nanoparticles.

**Methods**

**Species conservation**

\[ \frac{\partial C_i}{\partial t} = -\nabla \cdot N_i + R_i \]

Where:

- \( C_i \) = molar concentration of species \( i \)
- \( N_i \) = molar flux of species \( i \) (using fixed coordinates)
- \( R_i \) = net rate of formation of species \( i \) per unit volume

Assume \( i \) is a minor component in a pseudobinary, constant density, constant diffusivity liquid solution. Then:

\[ \frac{DC_i}{Dt} = D_i N_i^2 C_i + R_i \]

With no net rate of formation of species \( i \), and no flow:

\[ \frac{\partial C_i}{\partial t} = D_i \left[ \frac{1}{r^2} \frac{\partial}{\partial r} \left( r^2 \frac{\partial C_i}{\partial r} \right) + \frac{1}{r^2} \sin \theta \frac{\partial}{\partial \theta} \left( \sin \theta \frac{\partial C_i}{\partial \theta} \right) + \frac{1}{r^2} \frac{\partial^2 C_i}{\partial \phi^2} \right] \]

For a spherically symmetric, homogeneous drug-encapsulating MLV:

\[ \frac{\partial C}{\partial t} = D \left[ \frac{1}{r^2} \frac{\partial}{\partial r} \left( r^2 \frac{\partial C}{\partial r} \right) \right] \]

Where:

- \( C \) = concentration of the drug within the MLV
- \( D \) = diffusivity of the drug within the MLV
- \( t \) = elapsed time
Boundary conditions are:

\[ 0 < r < R \quad t \leq 0 \quad C = C_0 \]
\[ r = 0 \quad t \geq 0 \quad \frac{\partial C}{\partial r} = 0 \]
\[ r = R \quad t \geq 0 \quad \frac{\partial C}{\partial r} = -\frac{k_c}{D} C \]

Where:

\[ k_c = \text{mass transfer coefficient of the drug within the MLV} \]

Scale and nondimensionalize:

\[
\eta = \frac{r}{R}, \quad \theta' = \frac{C}{C_0}, \quad \tau = \frac{D}{R^2} t
\]

\[
\frac{\partial \theta'}{\partial \tau} = \frac{1}{\eta^2 \partial \eta} \left( \frac{\partial^2 \theta'}{\partial \eta^2} \right)
\]

\[
0 < \eta < 1 \quad \tau \leq 0 \quad \theta = 1
\]
\[ \eta = 0 \quad \tau \geq 0 \quad \frac{\partial \theta'}{\partial \eta} = 0 \]
\[ \eta = 1 \quad \tau \geq 0 \quad \frac{\partial \theta'}{\partial \eta} = -\frac{k_c R}{D} \theta'
\]

For ease of solution, transform:

\[
\theta(\eta, \tau) = 1 - \theta'(\eta, \tau)
\]

\[
\frac{\partial \theta}{\partial \tau} = \frac{1}{\eta^2 \partial \eta} \left( \frac{\partial^2 \theta}{\partial \eta^2} \right)
\]

\[
0 < \eta < 1 \quad \tau \leq 0 \quad \theta = 0, \theta' = 0
\]
\[ \eta = 0 \quad \tau \geq 0 \quad \frac{\partial \theta}{\partial \eta} = 0 \]
\[ \eta = 1 \quad \tau \geq 0 \quad \frac{\partial \theta}{\partial \eta} = \frac{k_c R}{D} (1 - \theta)
\]

Apply FFT to solve, seeking solution of the form:

\[
\theta(\eta, \tau) = \sum_{n=1}^{\infty} \theta_n(\tau) \phi_n(\eta)
\]

With basis functions:

\[
\phi_n(\eta) = \sqrt{2} \left[ \frac{1 - \frac{k_c R}{D}}{\sin^2 \lambda_n - \frac{k_c R}{D}} \right]^{1/2} \sin(\lambda_n \eta) \frac{\sin(\frac{\lambda_n R}{D})}{\eta}
\]

\[ \lambda_n = \left( 1 - \frac{k_c R}{D} \right) \tan \lambda_n, \quad n = 1, 2, \ldots \]

Transform:

\[
\frac{1}{\phi_n} \frac{\partial \theta}{\partial \tau} \eta^2 d\eta = \frac{d\theta_n}{d\tau}
\]

\[ \left[ \frac{1}{\phi_n} \frac{\partial \theta}{\partial \tau} \eta^2 d\eta \right]_{\eta=0}^{\eta=\lambda_n} = \eta^2 \left( \frac{\partial \theta_n}{\partial \tau} - \frac{\partial^2 \theta_n}{\partial \eta^2} \right)_{\eta=0} - \lambda_n^2 \theta_n \]

\[ = \sqrt{\frac{2}{\pi}} \frac{k_c R}{D} \left[ \frac{1 - \frac{k_c R}{D}}{\sin^2 \lambda_n - \frac{k_c R}{D}} \right]^{1/2} \sin \lambda_n - \lambda_n^2 \theta_n \]

Hence:

\[ \theta_n(0) = 0 \]

And:

\[ \theta(\eta, \tau) = \sum_{n=1}^{\infty} 2 \theta_n(\tau) \phi_n(\eta) \]

Which can be simplified upon inspection to:

\[ \theta(\eta, \tau) = 1 - \sum_{n=1}^{\infty} 2 \left[ \frac{1 - \frac{k_c R}{D}}{\sin^2 \lambda_n - \frac{k_c R}{D}} \right]^{1/2} \sin \lambda_n \frac{\sin(\lambda_n \eta) \exp[-\frac{\lambda_n^2 \tau}{2}]}{\eta} \]

Therefore, the final solution is:

\[ \theta(\eta, \tau) = \sum_{n=1}^{\infty} 2 \phi_n(\eta) \]

\[ \phi_n(\eta) = \sqrt{2} \left[ \frac{1 - \frac{k_c R}{D}}{\sin^2 \lambda_n - \frac{k_c R}{D}} \right]^{1/2} \sin(\lambda_n \eta) \frac{\sin(\frac{\lambda_n R}{D})}{\eta}
\]

\[ \lambda_n = \left( 1 - \frac{k_c R}{D} \right) \tan \lambda_n \]

\[ \eta = \frac{r}{R}, \quad \theta' = \frac{C}{C_0}, \quad \tau = \frac{D}{R^2} t \]

Linear momentum conservation

\[ \rho \frac{Dv}{Dt} = \rho g + \nabla \cdot \sigma \]

For a constant viscosity, constant density, incompressible Newtonian fluid:

\[ \rho \frac{Dv}{Dt} = \rho g - \nabla p + \mu \nabla^2 v \]

Or:

\[ \rho \frac{Dv}{Dt} = -\nabla p + \mu \nabla^2 v \]

Where:
\( \rho = \) dynamic pressure
Assume fully developed unidirectional flow. Then:

\[
\frac{\partial v_z}{\partial t} - \frac{\partial P}{\partial z} + \mu \left[ \frac{1}{r} \frac{\partial}{\partial r} \left( r \frac{\partial v_z}{\partial r} \right) + \frac{1}{r^2} \frac{\partial^2 v_z}{\partial \theta^2} \right]
\]

Further assume steady axisymmetric flow. Then:

\[
\frac{1}{r} \frac{d}{dr} \left( r \frac{d v_z}{d r} \right) = \frac{1}{\mu} \frac{d P}{d z}
\]

Integrate and apply symmetry condition at \( r = 0 \):

\[
\frac{r}{d}{v_z} = \frac{r^2}{2 \mu} \frac{dP}{d z}
\]

Integrate again and apply no-slip condition at \( r = R \) (\( R \) = vessel radius):

\[
v_z(r) = -\frac{R^2}{4 \mu} \frac{dP}{d z} \left\{ 1 - \left( \frac{r}{R} \right)^2 \right\}
\]

Or:

\[
v_z(r) = 2U \left\{ 1 - \left( \frac{r}{R} \right)^2 \right\}
\]

\[
U = -\frac{R^2}{8 \mu} \frac{dP}{d z}
\]

Per species conservation:

\[
\frac{DC_i}{Dt} = D_i \nabla^2 C_i + R_i
\]

Assume large Péctet number (axial diffusion negligible). Then:

\[
v_z \frac{\partial C}{\partial z} = D_i \left\{ \frac{1}{r \theta} \frac{\partial}{\partial r} \left( r \frac{\partial C}{\partial r} \right) \right\}
\]

Hence:

\[
2U \left\{ 1 - \left( \frac{r}{R} \right)^2 \right\} \frac{\partial C}{\partial z} = D_i \left\{ \frac{1}{r \theta} \frac{\partial}{\partial r} \left( r \frac{\partial C}{\partial r} \right) \right\}
\]

Where:
- \( C \) = liposome concentration within the vessel
- Integrate over \( r \):

\[
\int_0^R v_z \frac{\partial C}{\partial z} rdr = RD \frac{\partial C}{\partial r} \bigg|_{r=R} - RN_r
\]

Where:
- \( N_r \) = liposome flux

Also:

\[
\int_0^R v_z \frac{\partial C}{\partial z} rdr = \frac{R^2}{2} U \frac{dC_b}{dz}
\]

Where:
- \( C_b \) = \( \int_0^A C_v dA \) \( \int_0^A v_z dA \)
- \( A \) = cross-sectional area of the vessel

Apply the following correlations:

\[
N_r = k_c (C_b - C_{(r=R)})
\]

\[
N_r = k_m (C_{(r=R)} - C_t)
\]

\[
N_r = k_t C_t
\]

Where:
- \( C_t \) = liposome concentration in the tissue at the surface of the outer vessel wall

Then:

\[
\frac{dC_b}{dz} = -\frac{2k_c}{RU} (C_b - C_{(r=R)})
\]

And:

\[
C_b - C_{(r=R)} = \left( \frac{k_m k_t}{k_c (k_m + k_t) + k_m k_t} \right) C_b
\]

Therefore:

\[
\frac{dC_b}{dz} = -\frac{2}{RU} \left( \frac{k_m k_t}{k_c (k_m + k_t) + k_m k_t} \right) C_b
\]

Hence, the final solution is:

\[
C_b(0) = C_o
\]

\[
\frac{C_b}{C_o} = \exp \left[ -\frac{2z}{RU} \frac{k_m k_t}{k_c (k_m + k_t) + k_m k_t} \right]
\]

\[
U = -\frac{R^2}{8 \mu} \frac{dP}{d z}
\]

**CTR mole balance**

\[
\frac{dF_j}{dV} = r_j
\]

Assume low feed flow rate. Then:

\[
\frac{dC_j}{dL} = \frac{r_j}{u}
\]

Where:
- \( C_j \) = concentration of species \( j \)
- \( L \) = position in reactor
- \( u \) = feed flow rate
Assume constant reactor radius and constant flow. Then:

\[
\frac{dC_j}{dL} \approx \frac{d}{dL} \left( \frac{N_j}{V} \right) = \frac{d}{dL} \left( \frac{N_j}{A} \right) \frac{A}{V} = \frac{d}{dL} \left( \frac{2\pi r}{\pi r^2} \right) \frac{A}{2r} = \frac{d}{dL} \left( \frac{N_j}{A} \right) \frac{4}{d} \]

Where:
- \( A \) = area of reactor
- \( d \) = diameter of reactor
- \( N_j \) = number of moles of species \( j \)
- \( r \) = radius of reactor
- \( V \) = volume of reactor

Assume pseudo-second order kinetics with large excess of deposited lipid. Use:

100 Targeting Receptors (TR) \( \frac{1}{4} \times 10000 \) Drug (DRG) \( \frac{1}{4} \times 8000 \) Lipid (LIP) \( \frac{1}{4} \) Liposome (DEL) \( \frac{1}{4} \)

Then:

\[
\frac{d[TR]}{dL} = -\frac{1}{u} \left( \frac{40000}{d} \right) [TR][DRG]
\]
\[
\frac{d[DEL]}{dL} = \frac{1}{u} \left( \frac{4}{d} \right) [TR][DRG]
\]

Where:
- \( d \) = CTR diameter
- \( k \) = reaction rate coefficient
- \( u \) = feed flow rate in the CTR

Acknowledgments
The author thanks Victoria Dydek, Klavs Jensen, and William Deen for discussions and suggestions.

Author Contributions
Conceived and designed the experiments: AW. Performed the experiments: AW. Analyzed the data: AW. Contributed reagents/materials/analysis tools: AW. Wrote the paper: AW.

References
1. Wong A (2009) Modified epidermal growth factor receptor (EGFR)-bearing liposomes (MRBLs) are sensitive to EGF in solution. PLoS One 4: e7391.
2. Semple SC, Harasym TO, Clow KA, Ansell SM, Klimuk SK, et al. (2005) Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic acid. J Pharmacol Exp Ther 312: 1020–1026.
3. Johnston MJW, Semple SC, Klimuk SK, Edwards K, Eisenhardt ML, et al. (2006) Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. Biochim Biophys Acta 1758: 55–64.
4. Deen WM (1998) Analysis of transport phenomena. New York, NY: Oxford University Press.
5. Ross SM (1974) A mathematical model of mass transport in a long permeable tube with radial convection. J Fluid Mech 63: 157–175.
6. Colton CK, Smith KA, Strover P, Merrill JW (1971) Laminar flow mass transfer in a flat duct with permeable walls. AIChE J 17: 773–780.
7. Carneiro AL, Santana MHA (2004) Production of liposomes in a multitubular system useful for scaling up of processes. Prog Colloid Polym Sci 128: 273–277.
8. Fogler HS (2006) Elements of chemical reaction engineering. Upper Saddle River, NJ: Pearson Prentice Hall.
9. Kullberg EB, Bergstrand N, Carlsson J, Edwards K, Johnson M, et al. (2002) Development of EGF-conjugated liposomes for targeted delivery of boronated DNA-binding agents. Bioconjugate Chem 13: 737–743.
10. Ishida O, Maruyama K, Tanahashi H, Iwatsuru M, Sasaki K, et al. (2001) Liposomes bearing polyethylene glycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharm Res 18: 1042–1043.
11. Suita T, Kamidate T, Yonaiyama M, Watanabe H (1997) Characterization of horseradish peroxidase-encapsulated liposomes prepared by an extrusion technique. Anal Sci 13: 577–581.